Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients

References

• Clemmenson I, Petersen L C., Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986; 156: 327–33
   Google Scholar
• Fuhlendorff J, Clemmensen I, Magnusson S. Primary structure of tetranectin, a plasminogen kringle 4 binding plasma protein: Homology with asialoglycoprotein receptors and cartilage proteoglycan core protein. Biochemistry 1987; 26: 6757–64
   PubMed Web of Science ®Google Scholar
• Christensen L, Clemmensen I. Tetranectin immuno-reactivity in normal human tissues. Histochemistry 1989; 92: 29–35
   PubMedGoogle Scholar
• Christensen L, Clemmensen I. Differences in tetranectin immunoreactivity between benign and malignant breast tissue. Histochemistry 1991; 95: 427–33
   PubMedGoogle Scholar
• Jensen B A., McNair P, Hyldstrup L, Clemmensen I. Plasma tetranectin in healthy male and female individuals, measured by enzyme-linked immunosorbent assay (ELISA). J Lab Clin Med 1987; 110: 612–7
   PubMed Web of Science ®Google Scholar
• Jensen B A., Clemmensen I. Plasma tetranectin is reduced in cancer and related to metastasia. Cancer 1988; 62: 869–72
   PubMedGoogle Scholar
• Nielsen H, Clemmensen I, Nielsen H J., Drivsholm A. Decreased tetranectin in multiple myeloma. Am J Hematol 1990; 33(2)142–4
   Google Scholar
• Høgdall C K., Hogdall E V., Herding U, Daugaard S, Clemmensen I, Nergaard-Pedersen B, Toftager-Larsen K. Plasma tetranectin and ovarian neoplasms. Gynecol Oncol 1991; 43: 103–7
   PubMed Web of Science ®Google Scholar
• Swenerton K D., Hislop T G., Spinelli J, Le Riche J C., Yang N, Boyes D A. Ovarian carcinoma: A multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 264–9
   PubMed Web of Science ®Google Scholar
• Redman J R., Petroni G R., Saigo P E., Geller N L., Hakes T B. Prognostic factors in advanced ovarian carninoma. J Clin Oncol 1989; 4: 515–23
   Google Scholar
• Peto K, Pike M C., Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Cox D R. Regression models and life tables. J Roy Stat Soc B 1972; 34: 187–220
   Web of Science ®Google Scholar
• Borregaard N, Christensen L, Bjerrum O W., Birgens H S., Clemmensen I. Identification of a highly mobilizable subset of human neutrophil intracellular vescicles that contains tetranectin and latent alkaline phosphatase. J Clin Invest 1990; 85: 408–16
   PubMed Web of Science ®Google Scholar
• Danø K, Andreasen P A., Grandahl-Hansen J, Kristensen P, Neilsen L S., Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139–266
   PubMed Web of Science ®Google Scholar
• Peterson H I., Kjartansson I, Korsan-Bengtsen K, Rudenstam C M., Zettergren L. Fibrinolysis in human malignant tumors. Acta Chir Scand 1973; 139: 219–23
   PubMedGoogle Scholar
• Aasted B, Svanberg L, Nilsson I M. Fibrin degra-tion products and ovarian tumors. Br Med J 1971; 4: 458–9
   Google Scholar
• Malone J M., Wangensteen S L., Moore W S., Keown K. The fibrinolytic system: A key to tumor metastasis. Ann Surg 1979; 190: 342–8
   Google Scholar
• Christensen L, Johansen N, Jensen B A., Clemmensen I. Immunohistochemical localization of a novel, human plasma protein, tetranectin, in human endocrine tissues. Histochemistry 1987; 87: 195–9
   PubMedGoogle Scholar
• Bertelsen K, Jakobsen A, Andersen J E., et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28: 161–9
   PubMed Web of Science ®Google Scholar
• Young R C., Walton L A., Ellenberg S S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021–7
   PubMed Web of Science ®Google Scholar
• Gruppo Interegionale Cooperativo Oncologico Ginecologia. Randomized comparison of cisplatin with cycJophosphamide/cisplatin and with cyclo-phosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987; ii: 353–9
   Google Scholar
• Cruickshank D J., Fullerton W T., Klopper A. The clinical, significance of pre-operative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol 1987; 94: 692–5
   Google Scholar
• Piver M S., Lele S B., Marchetti D L., Baker T R., Tsukada Y, Emrich L J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progress-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988; 6: 983–9
   PubMed Web of Science ®Google Scholar
• Canney P A., Moore M, Wilkinson P M., James R D. Ovarian cancer antigen CA 125: A prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984; 50: 765–9
   PubMed Web of Science ®Google Scholar
• Mogensen O, Mogensen B, Jakobsen A. Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecol Oncol 1990; 37: 44–6
   Google Scholar
• Lavin P T., Knapp R C., Malkasian G, Whitney C W., Berek J C., Bast R C. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 1987; 69: 223–7
   PubMedGoogle Scholar
• Van der Burg M EL, Lammes F B., van Putten W U., Stoter G. Ovarian cancer: The prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol 1988; 30: 307–12
   PubMed Web of Science ®Google Scholar
• Kivinen S, Kuoppala T, Leppilampi M, Vuori J, Kauppila A. Tumor-associated antigen CA 125 before and during the treatment of ovarian carcinoma. Obstet Gynecol 1986; 67: 468–72
   PubMedGoogle Scholar